SCHEMBL4908985

SCHEMBL4908985

COc1ccc(-c2cc(-c3cc(NC(=O)NN)ccc3N(CCCl)CCCl)c3ccccc3n2)c(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.49
CA9 Q16790 3/20 0.49
CA12 O43570 2/20 0.49
CA1 P00915 2/20 0.49
KDM4E B2RXH2 4/20 0.49
KMT2A Q03164 3/20 0.49
POLB P06746 2/20 0.49
MEN1 O00255 2/20 0.49
TDP1 Q9NUW8 1/20 0.44
LMNA P02545 3/20 0.41
HPGD P15428 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TP53 P04637 1/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.40
GAA P10253 1/20 0.40
ADORA3 P0DMS8 2/20 0.40
HSP90AA1 P07900 1/20 0.40
IGF1R P08069 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4905121 0.94 CYP2D6 (0.44) CA2CA9CA12CA1KDM4E
SCHEMBL4910370 0.92 TACR3 (0.45) CA2CA9CA12CA1KDM4E
SCHEMBL4909819 0.91 CA9 (0.49) CA2CA9CA12CA1KDM4E
SCHEMBL4914093 0.90 MEN1 (0.48) KDM4EKMT2APOLBMEN1HPGD
SCHEMBL4911300 0.88 KMT2A (0.47) KDM4EKMT2AMEN1TDP1LMNA
SCHEMBL4907492 0.86 MAPT (0.49) KDM4EKMT2APOLBMEN1TDP1
SCHEMBL4910397 0.86 KDM4E (0.49) CA2CA9CA12CA1KDM4E
SCHEMBL4907199 0.84 TACR3 (0.41) CA2CA9CA12CA1KDM4E
SCHEMBL4909862 0.84 MAPT (0.42) CA2CA9CA12CA1KMT2A
SCHEMBL4912691 0.84 PLA2G2A (0.46) CA2CA9CA12CA1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222297-B2 e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma ACADEMIA SINICA (TW) 2012-07-17 US disclosed
US-20080171765-A1 Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents ACADEMIA SINICA (TW) 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171765-A1 Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents WEE1, PCNA, ATIC CA2 201/4885CA9 182/4885CA12 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.